{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:31:55Z","timestamp":1792067515623,"version":"4.4.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.lfs.2021.119760","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T11:20:49Z","timestamp":1624274449000},"page":"119760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity"],"prefix":"10.1016","volume":"280","author":[{"given":"Miguel","family":"Anjos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fontes-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera M.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119760_bb0005","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2021.119760_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","article-title":"Long-term and latent side effects of specific cancer types","volume":"101","author":"Gegechkori","year":"2017","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.lfs.2021.119760_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7812\/TPP\/14-241","article-title":"Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations","volume":"19","author":"Bodai","year":"2015","journal-title":"Perm. J."},{"key":"10.1016\/j.lfs.2021.119760_bb0025","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.118.039371","article-title":"Management of cardiovascular diseases in women with breast cancer","volume":"139","author":"Barish","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119760_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin. Med. Insights Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0035","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-018-0183-9","article-title":"Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17 \u00df -estradiol in female tumor-bearing spontaneously hypertensive rats","volume":"9","author":"Pokrzywinski","year":"2018","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.lfs.2021.119760_bb0045","first-page":"1916","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity","volume":"2016","author":"Ghigo","year":"1863","journal-title":"BBA - Mol. Cell Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2012","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.lfs.2021.119760_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.lfs.2021.119760_bb0060","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0065","first-page":"15","article-title":"Anthracycline - induced cardiotoxicity in the chemotherapy treatment of breast cancer : Preventive strategies and treatment (Review)","volume":"11","author":"Cai","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0075","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0080","first-page":"1","article-title":"Cardiotoxicity of targeted cancer drugs: concerns, \u201cthe cart before the horse\u201d, and lessons from trastuzumab","volume":"21","author":"Menna","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0085","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0090","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti- HER 2 Monoclonal antibody in woman who have HER2-overexpresing metastatic breast cancer","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0095","first-page":"1347","article-title":"Monoclonal antibody to HER-2\/neu receptor modulates repair of radiation- induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene","volume":"59","author":"Pietras","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0100","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: a \u201cdual-hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1758834012469429","article-title":"Gastric cancer and trastuzumab: first biologic therapy in gastric cancer","volume":"5","author":"Gunturu","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0110","first-page":"77","article-title":"Survival of metastatic gastric cancer: significance of age, sex and race\/ethnicity","volume":"2","author":"Yang","year":"2011","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.lfs.2021.119760_bb0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12609-017-0249-4","article-title":"Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer","volume":"9","author":"Nowsheen","year":"2017","journal-title":"Curr. Breast Cancer Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the treatment of breast cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.lfs.2021.119760_bb0130","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/mp100308n","article-title":"Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids","volume":"7","author":"Peetla","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2021.119760_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113959","article-title":"Drug uptake-based chemoresistance in breast cancer treatment","volume":"177","author":"Muley","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-1221-6","article-title":"Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16","volume":"9","author":"Sagwal","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2021.119760_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01262","article-title":"Updates in anthracycline-mediated cardiotoxicity","volume":"9","author":"Nebigil","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0150","first-page":"1","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0155","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/pgs-2018-0056","article-title":"Drug transporters and anthracycline-induced cardiotoxicity","volume":"19","author":"Huang","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.lfs.2021.119760_bb0160","first-page":"1","article-title":"Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy","author":"Guo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2021.119760_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20082041","article-title":"Twist and turn\u2014topoisomerase functions in mitochondrial DNA maintenance","volume":"20","author":"Goffart","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0175","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Saywer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0180","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2008.11.059","article-title":"Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs","volume":"378","author":"Ashley","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119760_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy \u2013 an update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000499383","article-title":"Treatment-induced cardiotoxicity in breast cancer: a review of the interest of practicing a physical activity","volume":"96","author":"Ginzac","year":"2019","journal-title":"Oncologia"},{"key":"10.1016\/j.lfs.2021.119760_bb0195","first-page":"1","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?","author":"Kalyanaraman","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2021.119760_bb0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-015-2786-8","article-title":"Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to doxorubicin in tumor-bearing spontaneously hypertensive rats","volume":"76","author":"Gonzalez","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/03602532.2017.1316285","article-title":"The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs","volume":"49","author":"Hrynchak","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.lfs.2021.119760_bb0210","first-page":"3","article-title":"Doxorubicin-induced cardiotoxicity: from mechanisms to development of efficient therapy","volume":"1","author":"dos Santos","year":"2018","journal-title":"Cardiotoxicity."},{"key":"10.1016\/j.lfs.2021.119760_bb0215","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1093\/nar\/gkn774","article-title":"Interaction of anthracyclines with iron responsive element mRNAs","volume":"36","author":"Canzoneri","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/mol.105.013383","article-title":"Molecular pharmacology of the interaction of anthracyclines with iron","volume":"68","author":"Xu","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom9030098","article-title":"The main metabolites of fluorouracil adriamycin cyclophosphamide (FAC) are not major contributors to FAC toxicity in H9C2 cardiac differentiated cells","volume":"9","author":"Reis-Mendes","year":"2019","journal-title":"Biomolecules."},{"key":"10.1016\/j.lfs.2021.119760_bb0230","first-page":"8422","article-title":"Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy","volume":"61","author":"Minotti","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1096\/fasebj.12.7.541","article-title":"The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase\/iron regulatory protein-1 in cytosolic fractions from human myocardium","volume":"12","author":"Minotti","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2021.119760_bb0240","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1211\/jpp.61.06.0016","article-title":"Glutathione depletion upregulates P-glycoprotein expression at the blood-brain barrier in rats","volume":"61","author":"Wu","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1124\/jpet.115.225490","article-title":"Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1\/Abcc1) null mices","volume":"355","author":"Deng","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2021.119760_bb0250","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/002215540205001008","article-title":"Expression and localization of P-glycoprotein in human heart: Effects of cardiomyopathy","volume":"50","author":"Meissner","year":"2002","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.lfs.2021.119760_bb0255","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-013-2260-4","article-title":"The role of antioxidants in the era of cardio-oncology","volume":"72","author":"Vincent","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0265","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovic","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2021.119760_bb0270","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","article-title":"The role of topoisomerase II\u00df in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane","volume":"20","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.lfs.2021.119760_bb0275","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119760_bb0280","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4330\/wjc.v6.i7.653","article-title":"Neuregulin-1\/erbB activities with focus on the susceptibility of the heart to anthracyclines","volume":"6","author":"Vasti","year":"2014","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0285","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1152\/ajpheart.01010.2008","article-title":"Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins","volume":"297","author":"Bian","year":"2009","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0290","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1152\/ajpheart.00268.2005","article-title":"Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure","volume":"289","author":"Liu","year":"2005","journal-title":"Am. J. Physiol - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0295","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-06-3721","article-title":"Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury","volume":"67","author":"Gabrielson","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0300","first-page":"2026","article-title":"NRG-1 - induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70 S6K, and MEK-MAPK-RSK","volume":"277","author":"Baliga","year":"2018","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.lfs.2021.119760_bb0305","doi-asserted-by":"crossref","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0310","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"JACC Basic to Transl. Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0315","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0320","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1111\/bph.12870","article-title":"Endothelin-1 contributes to endothelial dysfunction and enhanced vasoconstriction through augmented superoxide production in penile arteries from insulin-resistant obese rats: role of ETA and ETB receptors","volume":"171","author":"S\u00e1nchez","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0325","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1006\/bbrc.1993.1291","article-title":"Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro","volume":"191","author":"Suzuki","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119760_bb0330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0006-291X(89)92397-8","article-title":"Endothelin is a positive inotropic agent in human and rat heart in vitro","volume":"159","author":"Moravec","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119760_bb0335","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00005344-199100177-00052","article-title":"Endothelin-1 stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium","volume":"17","author":"Suzuki","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0340","first-page":"17","article-title":"Doxorubicin induced heart failure: phenotype and molecular mechanisms","volume":"10","author":"Mitry","year":"2016","journal-title":"IJC Hear. Vasc."},{"key":"10.1016\/j.lfs.2021.119760_bb0345","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1158\/0008-5472.CAN-07-1344","article-title":"The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy","volume":"67","author":"Bien","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0350","first-page":"233","article-title":"Mitochondrial dynamics in heart disease","volume":"2013","author":"Dorn","year":"1833","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0355","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0020-711X(94)90176-7","article-title":"Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity","volume":"26","author":"Sokolove","year":"1994","journal-title":"Int. J. Biochem."},{"key":"10.1016\/j.lfs.2021.119760_bb0360","first-page":"323","article-title":"Mitochondrial dysfunction associated with doxorubicin","volume":"13","author":"Guven","year":"2018","journal-title":"Mitochondrial Dis."},{"key":"10.1016\/j.lfs.2021.119760_bb0365","first-page":"810","article-title":"The role of mitochondrial cardiolipin in heart function and its implication in cardiac disease","volume":"2019","author":"Dudek","year":"1865","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.lfs.2021.119760_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0158376","article-title":"Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes","volume":"11","author":"Aryal","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.lfs.2021.119760_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/9601435","article-title":"Corrigendum to \u201cChemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib\u201d","volume":"2019","author":"Gorini","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2021.119760_bb0380","first-page":"1","article-title":"Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway","volume":"10","author":"He","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0385","first-page":"4592","article-title":"Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: bax ratio 1","volume":"4","author":"Childs","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0390","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/MCB.18.6.3518","article-title":"Opposing effects of jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy","volume":"18","author":"Nemoto","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lfs.2021.119760_bb0395","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lfs.2006.09.019","article-title":"Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-?B activation","volume":"80","author":"Kim","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0400","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvq361","article-title":"Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart","volume":"90","author":"Park","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0405","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1152\/ajpcell.2000.279.3.C868","article-title":"The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation","volume":"279","author":"Wang","year":"2000","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1254\/jphs.FP0050980","article-title":"Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo","volume":"101","author":"Ueno","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0415","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1073\/pnas.97.1.315","article-title":"Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy","volume":"97","author":"Kunisada","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119760_bb0420","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.freeradbiomed.2018.06.020","article-title":"Characterizations of mitochondrial uncoupling induced by chemical mitochondrial uncouplers in cardiomyocytes","volume":"124","author":"Gao","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0425","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1073\/pnas.2134694100","article-title":"Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age","volume":"100","author":"Jacoby","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119760_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2016.209","article-title":"Gp130-mediated STAT3 activation by s-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity","volume":"7","author":"Wu","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2021.119760_bb0435","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00395-010-0124-1","article-title":"Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia\/reperfusion","volume":"105","author":"Boengler","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0440","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.metabol.2018.07.004","article-title":"Sugar or fat: the metabolic choice of the trained heart","volume":"87","author":"Ferreira","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2021.119760_bb0445","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1152\/ajpheart.01057.2004","article-title":"Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply","volume":"289","author":"Tokarska-Schlattner","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0450","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1074\/jbc.M111.315812","article-title":"Inhibition of AMP-activated protein kinase a (AMPK a) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119760_bb0455","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.114.001180","article-title":"Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling potential role of energy metabolism remodeling","volume":"8","author":"Moulin","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.lfs.2021.119760_bb0460","first-page":"290","article-title":"Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress","volume":"94","author":"Kay","year":"2012","journal-title":"Cardiovascular Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0465","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lfs.2017.05.003","article-title":"Polyphenols, autophagy and doxorubicin-induced cardiotoxicity","volume":"180","author":"Shabalala","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0470","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119760_bb0475","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrendo.2014.35","article-title":"Autophagy - a key player in cellular and body metabolism","volume":"10","author":"Kim","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.lfs.2021.119760_bb0480","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bcp.2014.01.040","article-title":"Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK","volume":"88","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0485","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/cvr\/cvs282","article-title":"Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes","volume":"96","author":"Kawaguchi","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0490","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/jpet.111.189589","article-title":"Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2021.119760_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2016.01.002","article-title":"Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity","volume":"32","author":"Gu","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.113.000439","article-title":"Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy","volume":"2","author":"Xu","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2021.119760_bb0505","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.18632\/oncotarget.13596","article-title":"Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119760_bb0510","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","article-title":"Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119760_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tiv.2018.05.001","article-title":"Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1\/parkin pathway","volume":"51","author":"Yin","year":"2018","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.lfs.2021.119760_bb0520","first-page":"3360","article-title":"Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3","volume":"9","author":"Du","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.1000298","article-title":"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin","volume":"8","author":"Narendra","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.lfs.2021.119760_bb0530","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1083\/jcb.200910140","article-title":"PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy","volume":"189","author":"Matsuda","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.lfs.2021.119760_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.85817","article-title":"Heme oxygenase-1 regulates mitochondrial quality control in the heart","volume":"1","author":"Hull","year":"2016","journal-title":"JCI Insight."},{"key":"10.1016\/j.lfs.2021.119760_bb0540","doi-asserted-by":"crossref","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","article-title":"Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling","volume":"111","author":"Dhingra","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119760_bb0545","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2019\/9825061","article-title":"Mitophagy, mitochondrial dynamics, and homeostasis in cardiovascular aging","volume":"2019","author":"Wu","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2021.119760_bb0550","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.18632\/oncotarget.23543","article-title":"Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity","volume":"9","author":"Jiang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119760_bb0555","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.2002.03.090","article-title":"Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer","volume":"20","author":"Osoba","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open."},{"key":"10.1016\/j.lfs.2021.119760_bb0565","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib. Ther."},{"key":"10.1016\/j.lfs.2021.119760_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2021.119760_bb0575","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119760_bb0580","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2021.119760_bb0585","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","article-title":"How ERK1\/2 activation controls cell proliferation and cell death is subcellular localization the answer?","volume":"8","author":"Mebratu","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.lfs.2021.119760_bb0590","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5494\/wjh.v5.i2.63","article-title":"Progress in neuregulin\/ErbB signaling and chronic heart failure","volume":"5","author":"Yin","year":"2015","journal-title":"World J. Hypertens."},{"key":"10.1016\/j.lfs.2021.119760_bb0595","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119760_bb0600","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10863-009-9205-y","article-title":"Akt mediated mitochondrial protection in the heart: Metabolic and survival pathways to the rescue","volume":"41","author":"Miyamoto","year":"2009","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.lfs.2021.119760_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107159","article-title":"Early morphological changes in cardiac mitochondria after subcutaneous administration of trastuzumab in rabbits: possible prevention with oral selenium supplementation","volume":"44","author":"Laird-Fick","year":"2020","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.lfs.2021.119760_bb0610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2017.06.033","article-title":"Targeting proinflammatory cytokines, oxidative stress, TGF-\u00df1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity","volume":"93","author":"Kabel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2021.119760_bb0615","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/B978-0-12-381510-1.00014-4","article-title":"Cardiovascular mechanotransduction","volume":"1","author":"Dobner","year":"2012","journal-title":"Muscle."},{"key":"10.1016\/j.lfs.2021.119760_bb0620","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0625","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2 breast cancer treatment and cardiotoxicity: monitoring and management American Society of Clinical Oncology European Society of Cardiology","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lfs.2021.119760_bb0630","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","article-title":"Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes","volume":"7","author":"Gianni","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.lfs.2021.119760_bb0635","first-page":"857","article-title":"Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats","volume":"35","author":"Kertmen","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0640","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/ars.2012.4588","article-title":"Angiotensin II and oxidative stress in the failing heart","volume":"19","author":"Zablocki","year":"2013","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.lfs.2021.119760_bb0645","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1152\/ajpheart.00283.2009","article-title":"Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats","volume":"297","author":"Deschamps","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0650","doi-asserted-by":"crossref","first-page":"13092","DOI":"10.1074\/jbc.M601984200","article-title":"17\u00df-estradiol protects against oxidative stress-induced cell death through the glutathione\/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells","volume":"281","author":"Urata","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119760_bb0655","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biomed.2011.10.004","article-title":"Mechanisms governing the protective effect of 17\u00df-estradiol and estrogen receptors against cardiomyocyte injury","volume":"1","author":"Lin","year":"2011","journal-title":"Biomed."},{"key":"10.1016\/j.lfs.2021.119760_bb0660","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2005.08.056","article-title":"Effect of 17-\u00df-estradiol administration during adriamycin-induced cardiomyopathy in ovariectomized rat","volume":"523","author":"Mu\u00f1oz-Casta\u00f1eda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0665","first-page":"6","article-title":"Estrogen but not testosterone preserves myofilament function from doxorubicin-induced cardiotoxicity by reducing oxidative modifications","volume":"2","author":"Rattanasopa","year":"2018","journal-title":"Am. J. Physiol - Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0670","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5114\/aoms.2015.50969","article-title":"The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab","volume":"11","author":"Huszno","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-016-0012-4","article-title":"Doxorubicin cardiotoxicity and target cells: a broader perspective","volume":"2","author":"De Angelis","year":"2016","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.lfs.2021.119760_bb0680","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1152\/ajpheart.00035.2015","article-title":"Antiarrhythmic effect of growth factor-supplemented cardiac progenitor cells in chronic infarcted heart","volume":"310","author":"Savi","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0685","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2015.03.438","article-title":"SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells","volume":"189","author":"De Angelis","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0690","first-page":"676","article-title":"Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice","author":"Huang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119760_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-013-0334-4","article-title":"Doxorubicin induces senescence and impairs function of human cardiac progenitor cells","volume":"108","author":"Piegari","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0700","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.109.895771","article-title":"Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function","author":"De Angelis","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119760_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00635","article-title":"Mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy: potential mechanisms, governing factors, and implications of the heart stem cell debate","volume":"10","author":"Abushouk","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0710","article-title":"Doxorubicin cardiotoxicity: multiple targets and translational perspectives","author":"De Angelis","year":"2018","journal-title":"Cardiotoxicity."},{"key":"10.1016\/j.lfs.2021.119760_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0124643","article-title":"Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes","volume":"10","author":"Fabbi","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.lfs.2021.119760_bb0720","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00395-010-0102-7","article-title":"Hepatocyte growth factor\/met gene transfer in cardiac stem cells-potential for cardiac repair","volume":"105","author":"Madonna","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17101680","article-title":"Doxorubicin regulates autophagy signals via accumulation of cytosolic Ca2 in human cardiac progenitor cells","volume":"17","author":"Park","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119760_bb0730","first-page":"355","article-title":"Cardiac toxicity of trastuzumab in elderly patients with breast cancer","volume":"13","author":"Denegri","year":"2016","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0735","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5966\/sctm.2011-0016","article-title":"Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab","volume":"1","author":"Barth","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0740","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.307778","article-title":"Revisiting cardiac cellular composition","volume":"118","author":"Pinto","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0745","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1242\/bio.020362","article-title":"Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability","volume":"5","author":"Wilkinson","year":"2016","journal-title":"Biology Open."},{"key":"10.1016\/j.lfs.2021.119760_bb0750","first-page":"1929","article-title":"Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents","volume":"59","author":"Garner","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0755","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.freeradbiomed.2016.10.371","article-title":"Doxorubicin-mediated toxic effects are mediated via NO\/eNOS in a novel 3D in vitro model of the human heart","volume":"100","author":"Polonchuk","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0760","first-page":"11294","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin","volume":"36","author":"V\u00e1squez-Vivar","year":"1997","journal-title":"Society"},{"key":"10.1016\/j.lfs.2021.119760_bb0765","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1152\/ajpheart.00795.2008","article-title":"Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro","volume":"296","author":"Mukhopadhyay","year":"2009","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0770","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2021.119760_bb0775","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cardiores.2007.04.024","article-title":"Biochemistry of protein tyrosine nitration in cardiovascular pathology","volume":"75","author":"Peluffo","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0780","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjp.0704495","article-title":"Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase","volume":"135","author":"Mihm","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0785","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.vph.2010.08.001","article-title":"Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells","volume":"53","author":"Keltai","year":"2010","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2018.00101","article-title":"Cardiomyocyte\u2014endothelial cell interactions in cardiac remodeling and regeneration","volume":"5","author":"Talman","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0795","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2021.119760_bb0800","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1152\/ajpregu.00205.2015","article-title":"Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure","volume":"310","author":"Abukar","year":"2016","journal-title":"Am. J. Physiol. - Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0805","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2012.03.020","article-title":"Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease","volume":"84","author":"Mazzuca","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0810","first-page":"1147","article-title":"Endothelial dysfunction as a determinant of trastuzumabmediated cardiotoxicity in patients with breast cancer","volume":"34","author":"Sandoo","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0815","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/VHRM.S69641","article-title":"Breast cancer therapy and cardiovascular risk: focus on trastuzumab","volume":"11","author":"Sandoo","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.lfs.2021.119760_bb0820","doi-asserted-by":"crossref","first-page":"H443","DOI":"10.1152\/ajpheart.00176.2020","article-title":"The role of endothelial autocrine NRG1\/ERBB4 signaling in cardiac remodeling","volume":"319","author":"Dugaucquier","year":"2020","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0825","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehv564","article-title":"NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice","volume":"37","author":"Langbein","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2021.119760_bb0830","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/21645515.2015.1125056","article-title":"Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?","volume":"12","author":"Riccio","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.lfs.2021.119760_bb0835","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.hlc.2018.08.003","article-title":"Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts","volume":"28","author":"Levick","year":"2019","journal-title":"Hear. Lung Circ."},{"key":"10.1016\/j.lfs.2021.119760_bb0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0221940","article-title":"Doxorubicin induces trans-differentiation and MMP1 expression in cardiac fibroblasts via cell death-independent pathways","volume":"14","author":"Narikawa","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.lfs.2021.119760_bb0845","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/CIRCRESAHA.109.216101","article-title":"Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction","volume":"107","author":"Dobaczewski","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0850","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.redox.2015.09.009","article-title":"Reciprocal regulation of TGF-\u00df and reactive oxygen species: a perverse cycle for fibrosis","volume":"6","author":"Liu","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2021.119760_bb0855","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00210-019-01624-3","article-title":"Irbesartan suppresses cardiac toxicity induced by doxorubicin via regulating the p38-MAPK\/NF-?B and TGF-\u00df1 pathways","volume":"392","author":"El-Said","year":"2019","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119760_bb0860","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1152\/ajpheart.00747.2001","article-title":"Calcium- and superoxide anion-mediated mitogenic action of substance P on cardiac fibroblasts","volume":"282","author":"Kumaran","year":"2002","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0865","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/aps.2011.194","article-title":"Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats","volume":"33","author":"Ivanov\u00e1","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2021.119760_bb0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-5-15","article-title":"Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease","volume":"5","author":"Fan","year":"2012","journal-title":"Fibrogenes. Tissue Repair."},{"key":"10.1016\/j.lfs.2021.119760_bb0875","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.2147\/OTT.S106528","article-title":"Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking","volume":"9","author":"Coppola","year":"2016","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.lfs.2021.119760_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1089359","article-title":"Cardiac nonmyocyte cell functions and crosstalks in response to cardiotoxic drugs","volume":"2017","author":"Gambardella","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2021.119760_bb0885","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.rpor.2017.01.004","article-title":"Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy","volume":"22","author":"Yavas","year":"2017","journal-title":"Reports Pract. Oncol. Radiother."},{"key":"10.1016\/j.lfs.2021.119760_bb0890","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1540-8159.1997.tb06199.x","article-title":"Microfibrosis produces electrical load variations due to loss of side- to-side cell connections: a major mechanism of structural heart disease arrhythmias","volume":"20","author":"Spach","year":"1997","journal-title":"PACE - Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.lfs.2021.119760_bb0895","first-page":"383","article-title":"Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin\/trastuzumab-induced cardiac toxicity","volume":"116","author":"Milano","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2021.119760_bb0900","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2261-12-63","article-title":"Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response","volume":"12","author":"Hadi","year":"2012","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.lfs.2021.119760_bb0905","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-011-0165-2","article-title":"Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats","volume":"12","author":"El-Aziz","year":"2012","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119760_bb0910","first-page":"1916","article-title":"Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187","volume":"142","author":"Zhang","year":"1993","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2021.119760_bb0915","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.5192","article-title":"Doxorubicin-induced cardiotoxicity involves IFN ? -mediated metabolic reprogramming in cardiomyocytes","volume":"247","author":"Ni","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.lfs.2021.119760_bb0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep26489","article-title":"NLRP3 deficiency reduces macrophage interleukin-10 production and enhances the susceptibility to doxorubicin-induced cardiotoxicity","volume":"6","author":"Kobayashi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0925","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/cdd.2011.4","article-title":"TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation","volume":"18","author":"Krysko","year":"2011","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lfs.2021.119760_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00802","article-title":"Unique phenotypes of heart resident type 2 innate lymphoid cells","volume":"11","author":"Deng","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119760_bb0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-07328-z","article-title":"IL-4 as a repurposed biological drug for myocardial infarction through augmentation of reparative cardiac macrophages: proof-of-concept data in mice","volume":"7","author":"Shintani","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119760_bb0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2021.119760_bb0945","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/ajpheart.00253.2017","article-title":"Vitamin C mitigates oxidative\/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy","volume":"313","author":"Akolkar","year":"2017","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521007463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521007463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:49:58Z","timestamp":1758401398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521007463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":189,"alternative-id":["S0024320521007463"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119760","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119760"}}